MONROVIA, Calif.--(BUSINESS WIRE)--May 23, 2019--
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company
developing engineered monoclonal antibodies for the treatment of cancer,
autoimmune diseases, asthma and allergic diseases, today announced the
appointment of Jeremy Grunstein, Ph.D., as vice president, business
development. Dr. Grunstein brings more than 15 years of expertise in
partnering, acquisitions and licensing in the biopharmaceutical industry
and will lead strategic partnering to enhance the development of
Xencor’s pipeline of drug candidates.
“Xencor is building a large and diversified portfolio of drug candidates
using our XmAb® Fc platforms, and we will continue to leverage our
technologies with new research collaborations and transactions that
complement our internal pipeline,” said Bassil Dahiyat, Ph.D., president
and chief executive officer at Xencor. “We are thrilled to welcome
Jeremy and look forward to his leadership and contributions to our team.”
Dr. Grunstein joins Xencor from Amgen Inc., where he served in several
strategic business development roles. Most recently, he served as
executive director, transactions, where he led product and platform
technology transactions and managed Amgen’s out-licensing and corporate
equity portfolio. Prior to joining Amgen, Dr. Grunstein earned an MBA
from the Sloan School of Management at the Massachusetts Institute of
Technology and completed a post-doctoral fellowship in the Department of
Molecular Oncology at Genentech, Inc. He earned a Ph.D. in biology from
the University of California, San Diego, and a B.S. in biology from the
University of California, Los Angeles.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing
engineered monoclonal antibodies for the treatment of cancer, autoimmune
diseases, asthma and allergic diseases. Currently, 13 candidates
engineered with Xencor's XmAb® technology are in clinical development
internally and with partners. Xencor's XmAb antibody engineering
technology enables small changes to the structure of monoclonal
antibodies resulting in new mechanisms of therapeutic action. For more
information, please visit www.xencor.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are forward-looking statements within the meaning
of applicable securities laws, including, but not limited to, the
quotations from Xencor's president and chief executive officer and any
expectations relating to Xencor's financial expectations and business,
the timing and success of clinical trials, future product candidates,
Xencor's research and development programs, partnering efforts and
capital requirements. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements and the timing of events to be materially
different from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance or
results. Such risks include, without limitation, the risks associated
with the process of discovering, developing, manufacturing and
commercializing drugs that are safe and effective for use as human
therapeutics and other risks described in Xencor's public securities
filings. For a discussion of these and other factors, please refer to
Xencor's annual report on Form 10-K for the year ended December 31, 2018
as well as Xencor's subsequent filings with the Securities and Exchange
Commission. All forward-looking statements are based on Xencor's current
information and belief as well as assumptions made by Xencor. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and Xencor undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005215/en/
Source: Xencor, Inc.
Charles Liles
626-737-8118
cliles@xencor.com
Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com
